Becker & Associates Forms Strategic Alliance with China National Pharmaceutical Group Corporation

China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade), part of the largest pharmaceutical company in China, China National Pharmaceutical Group Corporation, has signed a cooperative agreement with Becker & Associates Consulting, a leading provider of FDA consulting services for the medical device, pharmaceutical and biologics industry.

BEIJING & WASHINGTON--(EON: Enhanced Online News)--China National Pharmaceutical Group Corporation (Sinopharm Group) of Beijing and Becker & Associates Consulting (BECKER & ASSOCIATES) of Washington, DC announced today that the two companies, both dominant players in their respective countries, have formed a strategic alliance designed to bring high-level clinical and regulatory consulting services to China, as well as identify medical devices, drugs and biologics to be exported to China and subsequently distributed by China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade).

“We are honored to be working with a company that has the breadth and vision of Sinopharm Foreign Trade”

The alliance brings together two leading healthcare powerhouses, and sets the stage for improved collaboration between Chinese and American medical device, pharmaceutical and biologics manufacturers. “We are honored to be working with a company that has the breadth and vision of Sinopharm Foreign Trade,” stated Karen Becker, PhD, CEO of BECKER & ASSOCIATES. “Our partner has a tremendous footprint in China as part of the Sinopharm Group, which manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China.”

The Sinopharm Group has 16 subsidiaries and operates approximately a thousand retail pharmacy chains. It also has operations in Africa, France, Germany, Hong Kong, the United States, and Vietnam. The Sinopharm Group is the top pharmaceutical distributor in China, with the largest distribution network and four modern logistic centers. It is the largest vaccine manufacturer as well as the leading manufacturer, distributor and seller of narcotics in China, and it owns the best pharmaceutical engineering research institutes.

BECKER & ASSOCIATES is currently managing several large projects in China, including advising a major Chinese pharmaceutical manufacturing company as it seeks to be the first Chinese company to gain FDA approval to sell finished goods in the United States. This process, a watershed moment in the Chinese pharmaceutical industry, also signifies an important regulatory milestone for the Peoples Republic of China, and sets the stage for significant growth in the Chinese pharmaceutical sector.

For additional information on the news in this release, contact Jack Kent or visit www.Becker-Consult.com.

About China National Pharmaceutical Foreign Trade Corporation:

Established in 1981, China National Pharmaceutical Foreign Trade Corporation is a wholly-owned subsidiary of China’s largest pharmaceutical group --- China National Pharmaceutical Group Corporation. Sinopharm Foreign Trade’s core business is the investment in, import and export, and domestic distribution of pharmaceuticals and related activities, including pharmaceutical R&D, consulting, bonded warehousing and other value-added services.

About BECKER & ASSOCIATES:

Becker & Associates Consulting, established in 2002, is among the leading scientific consulting firms in the United States. The Company specializes in guiding corporations through the clinical and regulatory process, and maintains perhaps the most highly regarded compliance practice for FDA regulated products.